Surrogate end points of renal failure are instrumental to the testing of new treatments in patients with chronic kidney disease, the natural history of which is characterized by a slow, asymptomatic decline in renal function. The magnitude of proteinuria is widely recognized as a marker of the severity of glomerulopathy. Population-based studies have identified proteinuria as a predictor of future decline in glomerular filtration rate and of the development of end-stage renal disease. More importantly, a reduction in proteinuria invariably translates into a protection from renal function decline in patients with diabetic and nondiabetic renal disease with overt proteinuria. Thus, proteinuria should be considered a valuable surrogate end point for clinical trials in patients with proteinuric renal diseases.
Proteinuria should be used as a surrogate in CKD / P. Cravedi, P. Ruggenenti, G. Remuzzi. - In: NATURE REVIEWS. NEPHROLOGY. - ISSN 1759-5061. - 8:5(2012 Mar), pp. 301-306.
|Titolo:||Proteinuria should be used as a surrogate in CKD|
REMUZZI, GIUSEPPE (Corresponding)
|Parole Chiave:||tubular epithelial-cells; type-1 diabetic-patients; post-hoc analysis; stage renal-disease; chronic nephropathies; kidney-disease; blood-pressure; nephrotic syndrome; overt nephropathy; progression|
|Settore Scientifico Disciplinare:||Settore MED/14 - Nefrologia|
|Data di pubblicazione:||mar-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/nrneph.2012.42|
|Appare nelle tipologie:||01 - Articolo su periodico|